Humira (Adalimumab) (Rheumatoid Arthritis) Market Size, Share, Trends and Forecasts to 2023

Humira (adalimumab) (Rheumatoid Arthritis) Market Size, Share, Trends,

Company Profiles, Demand, Insights, Analysis, Research, Report,

Opportunities, Segmentation and Forecast To 2023

Summary

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and

deformity of the joints. It affects over seven million individuals in the 10MM covered in this

report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the

prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have

been effective in treating the signs and symptoms of RA and inhibiting progression to erosive

bone disease. However, the landscape is quickly changing with the introduction of biosimilars,

novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change

the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective

therapies for RA, the market is extremely competitive for new entrants and will undergo further

pressure as biosimilars are approved and launch.

Humira (adalimumab) is a recombinant, fully-human, IgG1 mAb that binds to TNFa and blocks

its interaction with the p55 and p75 cell-surface receptors, which reduces inflammation and

prevents tissue destruction. It was the first fully-humanized mAb TNF inhibitor to enter the

market for the treatment of RA.

Access Full Report: http://www.radiantinsights.com/research/humira-adalimumabrheumatoid-arthritis-forecast-and-market-analysis-to-2023

Scope

- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis,

pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Humira (Adalimumab) including product description, safety and

efficacy profiles as well as a SWOT analysis.

- Sales forecast for Humira (Adalimumab) for the top 9 countries from 2013 to 2023.

- Sales information covered for the US, France,...